Month: May 2023

Abu Dhabi, May 02, 2023 (GLOBE NEWSWIRE) — Three high school students – Andrea Olsen from Oslo, Norway; Zachary Harpaz from Boca Raton, Florida; and Chris Ren from Shanghai, China – co-authored a paper using a generative artificial intelligence (AI) engine for target discovery from Insilico Medicine (“Insilico”) called PandaOmics to identify new therapeutic targets for glioblastoma multiforme (GBM). GBM is the most aggressive and common malignant brain tumor, accounting for 16% of all primary brain tumors. The findings were published on April 26 in the journal Aging.

Much of the technology behind PandaOmics is being developed in Insilico’s Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.

Olsen, a student at Sevenoaks School in Kent, UK, began interning at Insilico Medicine in 2021, after discovering her interest in neurobiology and technology. For the current paper, the fifth scientific paper she has co-authored before turning eighteen, she and other researchers used PandaOmics to screen datasets from the Gene Expression Omnibus repository maintained by the National Center for Biotechnology Information and found new therapeutic targets implicated for treating both aging and glioblastoma multiforme.

Ren, a student at Shanghai High School International Division, has an interest in biology and biomarkers and joined them in the summer of 2022.

While there would seem to be a clear connection between aging and cancer, Olsen says their findings were more nuanced. “Sometimes, instead of aging, the body switches to cancer mechanisms, which was really interesting to discover.” She hypothesized that “the body is trying to preserve itself in a way that it is switching back to embryonic processes of cell division.” GBM is caused by a genetic mutation that leads to uncontrolled growth of glial cells, or cells that surround neurons in the brain. Even with existing therapies, the median survival for GBM patients is only 15 months.

Harpaz, a student at Pine Crest School in Ft. Lauderdale, had an early interest in computer science and AI and soon developed a passion for biology as well. “I wanted to combine my two favorite topics, computer science and biology, into what I think is the most interesting field of biology – aging research,” Harpaz says. He discovered generative AI drug discovery company Insilico Medicine whose founder and CEO, Alex Zhavoronkov, PhD, connected him with Olsen. The two young researchers began collaborating on the glioblastoma project and ultimately presented findings at the Aging Research and Drug Discovery (ARDD) conference in Copenhagen, where they together launched the Youth Longevity Association (TYLA).

In this latest paper, the three teens used PandaOmics to analyze the genes and identified three that were strongly correlated with both aging and glioblastoma and could serve as potential therapeutic targets for new drugs.

“We selected the genes that were overlapped to be highly correlated in 11 of the 12 datasets, and we split our data into young, middle aged, and senior groups,” said Harpaz. “We mapped this to the importance of the gene expression to survival.” After identifying two genetic targets for glioblastoma and aging – CNGA3 and GLUD1 – they cross-referenced their findings with earlier findings from Insilico around genes strongly correlated with aging and identified a third target – SIRT1.

“I learned a lot about conducting a research project,” said Ren, who helped review the three targets. “The PandaOmics platform really made the project accessible to me. As a high school sophomore, I did not have sufficient experience for advanced research and analysis, however, I was still able to navigate the PandaOmics platform after a brief period of training to process and compare datasets of glioblastoma.”

The students say they are eager to continue their studies in AI and biology into college and to move the GBM research forward from target discovery to drug development.

“The best way to take this research further is going to be using Insilico’s Chemistry42 software, where we can take the targets we identified through PandaOmics and generate small molecules, potential drugs, with these targets that have the potential to treat glioblastoma and aging at the same time,” says Harpaz.

Prior to her internship at Insilico, Olsen says: “I never knew that AI could be so helpful in finding completely new therapeutic targets. For me, that was an incredible opportunity to dive into the field of research, aging, longevity, and neuroscience. It really kick-started my entire career.”

“I am truly impressed by the commitment of these young researchers,” says Zhavoronkov. “I hope their work will inspire other young people excited about science and technology to look at how they can use AI tools to discover new targets and treatments for both aging and disease.”

 

About Insilico Medicine

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. In early 2023, the Company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the region’s largest AI-powered biotechnology research center. The R&D hub brings together global talent in artificial intelligence and software development to expand the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support the digital transformation of healthcare in the region.

For more information, visit www.insilico.com

Attachment

• Students Use Insilico Medicine’s AI Platform to Find Targets for Glioblastoma and Aging

Jamila Alhammadi 
Insilico Medicine
475-225-0843
j.alhammadi@insilicomedicine.com

GlobeNewswire Distribution ID 8829593

• Environmental Product Declarations (EPDs) provide detailed information about each aircraft’s environmental footprint across its life cycle
• Bombardier’s unique Product Sustainability and Strategy team analyzed environmental incidence of over 140K aircraft parts per program to create holistic and transparent public reports
• Long-range Global 5500 and Global 6500 aircraft join Global 7500 and Challenger 3500 as world’s only business jets carrying an EPD
• Global 5500 and Global 6500 EPDs contribute to Bombardier’s long-term view EcoJet research platform

MONTREAL, May 02, 2023 (GLOBE NEWSWIRE) — Bombardier today announced that it has completed a thorough analysis of the Global 5500 and Global 6500 in order to publish Environmental Product Declarations (EPDs) for two of its large aircraft. They join the Global 7500 aircraft and the Challenger 3500 aircraft as business aviation’s only EPD-designated jets.

For over a decade, Bombardier dedicated a full-time internal team of experts to the development of standardizable key metrics, data gathering, validation and analysis. Bringing together industry players and 45 tier-1 suppliers, Bombardier assessed 200K aircraft parts over the development of the Global 7500 aircraft program, gaining valuable insights on the environmental impact of this business jet and leading to a third-party verified public report.

The industry-leading, high-performance Global 7500 aircraft became the first business aircraft to receive an EPD designation for this report in 2020 and was followed by the Challenger 3500 EPD in 2022. The holistic methodology was replicated in analyzing the Global 5500 and Global 6500 programs, where 280K parts were assessed.

“The publication of the Global 5500 and Global 6500 aircraft EPDs are the results of years of scientific effort,” said Michel Ouellette, Executive Vice President, Engineering and Product Development, Bombardier. “These declarations are more than brochures: they are tools for the aviation industry to drive sustainable innovations across its activities spectrum. They are also the outcome of the thoroughness, mindfulness and ingenuity of a uniquely skilled internal team of experts. As a company, we are immeasurably proud that the reputation of our products and exciting opportunities attract the best minds in the world.”

Thanks to the colossal groundwork done by Bombardier’s dedicated team in establishing environmental requirements at the design phase of future programs, the Global 5500 and Global 6500 business jets possess strong sustainability elements. From a design perspective, they feature up to 13% better fuel efficiency than their predecessors with redesigned wings and new purpose-built Rolls-Royce Pearl engines. The high-speed transonic wing on these aircraft also cuts down on drag, reducing fuel burn, and lowering emissions, offering a smooth ride, excellent short-field and high-speed performance. Bombardier also currently offers sustainable cabin material options for the interior of all aircraft.

“Bombardier has the influence and expertise to change the future of aviation,” said Michel Ouellette, “We made the decision over 10 years ago to tackle the industry’s most urgent challenge in the long run with our EcoJet research platform; in the short run by encouraging the increased use of Sustainable Aviation Fuels (SAF); and in the medium run by adopting a sustainability mindset when designing all our aircraft; before the first piece of sheet metal is cut. With our business jets EPDs, we have equipped ourselves with a comprehensive and replicable methodology to ensure environmental risks and impacts across our value chain are identified now, and effectively managed through our continuous innovation and improvement approach.”

The extensive data gleaned in the development of Bombardier’s product life cycle analysis, which is available for the industry and the public to consult, help key players reevaluate how current aircraft are designed and built. Bombardier’s sustainable cabin interiors materials offering is one example of how this life cycle analysis led to tangible product improvement. Meanwhile, in working towards inventing the future of sustainable aviation with its long-term view EcoJet research platform, these EPDs are already influencing decisions at the supply chain level, by mapping a clear strategy for sustainable sourcing and product development processes.

Bombardier’s overall environmental, social and governance (ESG) plan also supports the industry-wide aspiration to achieve net zero emissions by 2050, by actively advocating for the adoption of Sustainable Aviation Fuels, enhancing aircraft recoverability and sustainable sourcing, improving energy efficiency in its operations, optimizing carbon offsets, and more.

About Bombardier

Bombardier (BBD-B.TO) is a global leader in aviation, focused on designing, manufacturing, and servicing the world’s most exceptional business jets. Bombardier’s Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance, and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments, and private individuals. Bombardier aircraft are also trusted around the world in government and military special-mission roles leveraging Bombardier Defense’s proven expertise.

Headquartered in Greater Montréal, Québec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company’s robust customer support network services the Learjet, Challenger and Global families of aircraft, and includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China and Australia.

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with Sustainable Aviation Fuel (SAF) utilizing the Book and Claim system visit bombardier.com. Learn more about Bombardier’s industry-leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier, Challenger, Challenger 3500, Global, Global 5500, Global 6500 and Global 7500 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

For Information
Marie-Andrée Charron
Bombardier
+1 514-441-2598
marie-andree.charron@aero.bombardier.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6f8246dc-ff6c-4ed2-99bf-e5e429d82aa8

GlobeNewswire Distribution ID 8829771

NEW YORK, April 30, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Norfolk Southern Corporation (NYSE: NSC) between October 28, 2020 and March 3, 2023, both dates inclusive (the “Class Period”), of the important May 15, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Norfolk Southern securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Norfolk Southern class action, go to https://rosenlegal.com/submit-form/?case_id=12322 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 15, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: During the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s Precision Scheduled Railroading (“PSR”), including its use of longer, heavier trains staffed by fewer personnel, had led to the Company suffering increased train derailments and a materially increased risk of future derailments; (2) the Company’s PSR, including its use of longer, heavier trains staffed by fewer personnel, was part of a culture of increased risk-taking at the expense of reasonable safety precautions due to the Company’s near-term focus solely on profits; (3) the Company’s PSR, including its use of longer, heavier trains staffed by fewer personnel, rendered the Company more vulnerable to train derailments and train derailments with potentially more severe human, financial, legal, and environmental consequences; (4) the Company’s capital spending and replacement programs were designed to prioritize profits over the Company’s ability to provide safe, efficient, and reliable rail transportation services; (5) the Company’s lobbying efforts had undermined the Company’s ability to provide safe, efficient, and reliable rail transportation services; (6) the Company’s commitment to reducing operating expenses as part of its PSR goals undermined worker safety and the Company’s purported “commitment to an injury free workplace” because the Company’s PSR plan prioritized reducing expenses through fewer personnel, longer trains, and less spending on safety training, technology, and equipment such as hot bearing wayside detectors (a/k/a “hotboxes”) and acoustic sensors; (7) the Company’s rail services were, as a result of its adoption of PSR principles, more susceptible to accidents that could cause serious economic and bodily harm to the Company, the Company’s workers, the Company’s customers, third parties, and the environment; (8) the Company had failed to put in place responsive practices and procedures to minimize the threat to communities in the event that these communities suffered the derailment of a Norfolk Southern train carrying hazardous and toxic materials; and (9) as a result, defendants’ Class Period statements detailed above regarding the safety of Norfolk Southern’s operations were materially false and/or misleading.

To join the Norfolk Southern class action, go to https://rosenlegal.com/submit-form/?case_id=12322 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8828189